Company Description
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections.
The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Sam Lee Ph.D. |
Contact Details
Address: 19805 North Creek Parkway Bothell, Washington 98011 United States | |
| Phone | 877 262 7123 |
| Website | cocrystalpharma.com |
Stock Details
| Ticker Symbol | COCP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001412486 |
| CUSIP Number | 19188J300 |
| ISIN Number | US19188J4094 |
| Employer ID | 35-2528215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James J. Martin CPA, M.B.A. | Co-Chief Executive Officer, Chief Financial Officer and Corporate Secretary |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-Chief Executive Officer and President |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2025 | 8-K | Current Report |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 5, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | PRE 14A | Other preliminary proxy statements |